GlassScriptPhysician profile
Julius I Ejiofor
NPI 1629335039
$4,094.76
in general payments reported to CMS, 2019-2025
9 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2021: $589 · 2022: $435 · 2023: $611 · 2024: $761 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Travel and Lodging: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.52 |
| Travel and Lodging | $762.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,240.12 | 2019-2025 | Sapien 3 Ultra Resilia, Mitris Resilia Mitral Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bolton Medical INC | $1,020.31 | 2025 | Thoraflex Hybrid, Treo Abdominal Stent-Graft System, Relay Thoracic Stent-Graft With Plus Delivery System |
| W. L. Gore & Associates, INC. | $662.60 | 2023-2024 | Gore Tag Thoracic Endoprosthesis, Product In Development, Gore Tag Thoracic Branch Endoprosthesis |
| Medtronic, INC. | $445.12 | 2021-2025 | Corevalve Evolut R |
| Abiomed | $277.98 | 2023 | Impella |
| Medical Device Business Services, INC. | $200.69 | 2021 | |
| Becton, Dickinson and Company | $192.31 | 2022 | |
| Viz.Ai, INC. | $28.28 | 2022 | |
| Atricure, INC. | $27.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Ejiofor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.